Chemours Company (The) (NYSE:CC) had its target price upped by stock analysts at UBS Group AG (USA) from $50.00 to $59.00 in a research report issued to clients and investors on Friday, www.benzinga.com reports. The firm presently has a “neutral” rating on the specialty chemicals company’s stock. UBS Group AG (USA)’s price target indicates a potential upside of 13.11% from the company’s previous close.

A number of other brokerages have also weighed in on CC. Zacks Investment Research upgraded Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $61.00 price target for the company in a research note on Tuesday, October 3rd. BidaskClub upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Wednesday, July 12th. J P Morgan Chase & Co boosted their price target on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research note on Friday, August 4th. Jefferies Group LLC boosted their price target on Chemours Company (The) to $60.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Argus restated a “buy” rating and set a $55.00 price target (up from $50.00) on shares of Chemours Company (The) in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $53.88.

Chemours Company (CC) traded down $4.81 during trading hours on Friday, reaching $52.16. 8,803,630 shares of the company traded hands, compared to its average volume of 1,655,138. The company has a market capitalization of $9,639.22, a PE ratio of 18.50, a P/E/G ratio of 0.93 and a beta of 3.59. Chemours Company has a twelve month low of $16.39 and a twelve month high of $58.08. The company has a current ratio of 1.97, a quick ratio of 1.48 and a debt-to-equity ratio of 7.09.

Chemours Company (The) (NYSE:CC) last announced its quarterly earnings data on Thursday, November 2nd. The specialty chemicals company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.01 by $0.11. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.59 billion. Chemours Company (The) had a return on equity of 155.80% and a net margin of 4.86%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 earnings per share. analysts predict that Chemours Company will post 3.63 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Chemours Company (The) (CC) Price Target Increased to $59.00 by Analysts at UBS Group AG (USA)” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/04/chemours-company-the-cc-price-target-increased-to-59-00-by-analysts-at-ubs-group-ag-usa.html.

In other Chemours Company (The) news, SVP David C. Shelton sold 19,000 shares of the company’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $53.68, for a total value of $1,019,920.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Amy Trojanowski sold 2,500 shares of the company’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.03, for a total value of $115,075.00. The disclosure for this sale can be found here. Insiders have sold a total of 77,142 shares of company stock worth $3,953,265 over the last ninety days. Insiders own 1.14% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of CC. AJO LP bought a new stake in Chemours Company (The) during the second quarter valued at about $49,809,000. TIAA CREF Investment Management LLC boosted its position in Chemours Company (The) by 126.5% during the second quarter. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company’s stock valued at $67,843,000 after purchasing an additional 999,380 shares in the last quarter. Sirios Capital Management L P bought a new stake in Chemours Company (The) during the second quarter valued at about $37,430,000. FMR LLC boosted its position in Chemours Company (The) by 6.1% during the second quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock valued at $600,289,000 after purchasing an additional 905,038 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. bought a new stake in Chemours Company (The) during the second quarter valued at about $33,541,000. 72.99% of the stock is currently owned by institutional investors and hedge funds.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.